Elevance Health (NYSE:ELV) Announces Earnings Results

Elevance Health (NYSE:ELV) released its quarterly earnings data on Wednesday. The company reported $3.33 earnings per share for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23, FiscalAI reports. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The firm had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. During the same quarter in the prior year, the company posted $3.84 earnings per share. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Elevance Health updated its FY 2026 guidance to 25.500- EPS.

Elevance Health Stock Up 3.5%

ELV stock opened at $334.20 on Wednesday. The company’s 50 day moving average price is $350.06 and its 200 day moving average price is $328.78. The firm has a market capitalization of $74.27 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 1.94 and a beta of 0.51. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.56 and a current ratio of 1.56.

Institutional Trading of Elevance Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. boosted its holdings in shares of Elevance Health by 22.9% in the third quarter. Invesco Ltd. now owns 2,597,488 shares of the company’s stock valued at $839,300,000 after acquiring an additional 484,303 shares in the last quarter. Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of Elevance Health by 44.2% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company’s stock valued at $660,935,000 after buying an additional 627,038 shares during the period. Baupost Group LLC MA boosted its stake in shares of Elevance Health by 114.1% in the third quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company’s stock valued at $426,195,000 after buying an additional 703,000 shares in the last quarter. AQR Capital Management LLC grew its holdings in Elevance Health by 216.3% during the third quarter. AQR Capital Management LLC now owns 801,268 shares of the company’s stock worth $258,689,000 after acquiring an additional 547,950 shares during the period. Finally, Raymond James Financial Inc. lifted its holdings in Elevance Health by 100.8% in the second quarter. Raymond James Financial Inc. now owns 533,439 shares of the company’s stock valued at $207,486,000 after acquiring an additional 267,845 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 EPS beat expectations: Elevance reported $3.33 EPS vs. $3.07 consensus, showing operating profitability resilience even as revenue narrowly missed estimates. Read More.
• Neutral Sentiment: Company message and materials emphasize disciplined execution and investments to improve affordability and member experience — a strategic tone that is constructive but does not offset guidance concerns. Read More.
• Negative Sentiment: FY‑2026 EPS guidance came in below Wall Street expectations (Elevance gave ~25.50 vs. consensus ~26.89), directly pressuring forward valuation and near‑term earnings growth assumptions. Read More.
• Negative Sentiment: Elevated medical costs are expected to persist into 2026, which the company cites as the primary reason for the lower profit outlook — a margin risk that will weigh on investor sentiment until costs normalize. Read More.
• Negative Sentiment: Broader industry pressure: the Trump administration’s proposal to keep Medicare Advantage rates roughly flat next year is a sector headwind that amplifies concerns about insurer revenue and profitability. This policy news hit other major insurers and spilled over to Elevance. Read More.
• Negative Sentiment: Market reaction/coverage: media and analyst notes highlight the combination of below‑street guidance and Medicare rate risk, contributing to additional selling pressure and headlines that can exacerbate short‑term volatility. Read More.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Truist Financial set a $400.00 price target on Elevance Health in a research report on Tuesday, October 14th. JPMorgan Chase & Co. upped their price objective on shares of Elevance Health from $384.00 to $394.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 28th. Wells Fargo & Company raised their target price on shares of Elevance Health from $403.00 to $424.00 and gave the company an “overweight” rating in a research report on Wednesday, January 7th. The Goldman Sachs Group began coverage on shares of Elevance Health in a research note on Tuesday, October 14th. They set a “neutral” rating and a $343.00 price objective on the stock. Finally, Mizuho set a $413.00 target price on Elevance Health in a report on Friday, January 9th. Twelve research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $399.63.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.